HIGHLIGHTS
- who: Yan Xiang and colleagues from the Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China have published the Article: Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer, in the Journal: (JOURNAL)
- what: Since the discovery of the EML4-ALK fusion in NSCLC, a variety of ALK-TKIs have been developed to treat ALK-positive NSCLC.
SUMMARY
Anaplastic lymphoma kinase (ALK) mutation plays an important role in the occurrence and development of non-small cell lung cancer. Unlike the classic EML4-ALK, some . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.